Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Expected Spread Of US OTC Diagnostics Could Change Consumers’ Health Care Behaviors

Executive Summary

Diagnostics platform provider Ash Wellness expects at-home test providers can help improve consumers’ long-term health care outcomes with follow-up and ongoing communications for users of their products, influencing them to change behaviors.

You may also be interested in...



First Condom Authorized For US Market With Anal Sex Indication

The de novo authorization included the creation of a 510(k) pathway for similar devices in the future, allowing other condoms with the same function to reach market more easily.

Condom Approved In US With Anal Sex Indication Through FDA Process Encouraging More Proposals

With approval, FDA created regulatory classification allowing subsequent devices of same type with same intended use may go through 510(k) pathway, allowing devices to obtain clearance by demonstrating substantial equivalence to a predicate device.

With Market For COVID Tests, Face Masks Likely To Last, Senators Suggest Requiring Efficacy Labeling

Consumer Protection, Product Safety And Data Security Subcommittee hearing ventures past enforcement against false advertising for COVID-19 products and sales of fraudulently labeled products to criticism of e-commerce and social media providers for not keeping those products off their digital platforms.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT145495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel